Braxia Scientific Acquires KetaMD to Expand U.S. Telemedicine Ketamine Services
August 3, 2022
Braxia Scientific Corp. acquired 100% of KetaMD, a U.S.-based telemedicine platform offering at‑home, medically supervised ketamine treatments, in a share purchase completed in August 2022. The acquisition gives Braxia digital telehealth capabilities to complement its clinics and R&D, with KetaMD continuing to operate under its own brand and plans to expand beyond Florida into other U.S. states.
- Buyers
- Braxia Scientific Corp.
- Targets
- KetaMD, Inc.
- Sellers
- KetaMD common shareholders
- Industry
- Healthcare Services
- Location
- Florida, United States
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
BayMark Health Services Acquires Kaden Health
January 5, 2022
Healthcare Services
BayMark Health Services has acquired Kaden Health, an online addiction-treatment and telemedicine platform that provides virtual medication-assisted treatment (vMAT) for opioid use disorder. The purchase brings Kaden’s AI-enabled virtual care platform and development team into BayMark’s network to expand virtual access to treatment across its 350+ locations and to enable future licensing of the technology to other providers.
-
MediQuant Acquires Knowledge Based Systems (KBS)
October 27, 2022
Data & Analytics
MediQuant, a provider of enterprise data archive technology for healthcare, has completed the acquisition of Knowledge Based Systems, Inc. (KBS), a Dulles Technology Corridor–based company and creator of the KB_SQL product. The tuck-in purchase expands MediQuant's data management capabilities and opens additional channels and markets for its DataArk platform and related offerings.
-
MoodSpark (Telememory Holding Corp) Acquires Dthera Sciences
May 11, 2022
Medical Devices
Telememory Holding Corp (dba MoodSpark) has acquired Dthera Sciences, a San Diego–based pioneer in digital therapeutics, bringing Dthera’s FDA Breakthrough-designated device, patents, and clinical pilot research under the MoodSpark platform. The deal expands MoodSpark’s intellectual property and clinical capabilities in digital reminiscence therapy and cognitive behavioral interventions for seniors with Alzheimer’s and dementia, accelerating its offering for senior and veteran populations.
-
Kester Capital Acquires EMAS Pharma (carve-out from Bionical Emas)
December 24, 2024
Healthcare Services
Kester Capital has acquired EMAS Pharma, the clinical development division of Bionical Emas, in a carve-out transaction alongside an incoming executive team led by experienced CRO operators. The deal creates an independent CRO platform that Kester and the management team intend to scale organically and through acquisitions, expanding capabilities and geographic presence in North America and Europe.
-
KKR Acquires Majority Interest in Therapy Brands
April 7, 2021
Software
KKR has agreed to acquire a majority interest in Therapy Brands, a Birmingham-based practice management and EHR software platform for mental, behavioral and rehabilitation healthcare providers. Existing investor PSG will remain a minority shareholder, and sellers include investment funds affiliated with Lightyear Capital, Oak HC/FT and Greater Sum Ventures; financial terms were not disclosed.
-
K Health Acquires Trusst
August 24, 2021
Healthcare Services
K Health has acquired Trusst, a messaging-based mental health app, to integrate text-based therapy and simulated expert conversations into its virtual primary care platform. Trusst founder Bill Hudenko, Ph.D., will join K Health as Global Head of Mental Health; terms of the deal were not disclosed.
Track M&A activity that matters to you
Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.